# KBTBD6

## Overview
KBTBD6 is a gene that encodes the protein kelch repeat and BTB domain containing 6, which is a crucial component of cellular protein regulation mechanisms. This protein functions primarily as a substrate adaptor within the CUL3-RING E3 ubiquitin ligase complex, facilitating the ubiquitination and subsequent proteasomal degradation of target proteins. Notably, KBTBD6 is involved in the regulation of the dopamine receptor D2 (DRD2), impacting cellular signaling pathways related to dopamine response (Liu2020The). Additionally, KBTBD6 plays a role in telomere length regulation, suggesting its involvement in broader cellular maintenance processes (Keener2023Validation). The protein's interactions, particularly with KBTBD7 and GABARAP, underscore its significance in autophagy and tumor progression pathways (Genau2015GABARAP). Understanding the functions and interactions of KBTBD6 is essential for elucidating its potential impact on disease mechanisms and therapeutic strategies.

## Function
KBTBD6 is involved in the regulation of protein stability and degradation through its role as a component of an E3 ubiquitin ligase complex. This complex, which includes CUL3 and KBTBD7, facilitates the ubiquitination of target proteins, marking them for degradation by the proteasome. In particular, KBTBD6, along with KBTBD7, regulates the stability of the dopamine receptor D2 (DRD2) by promoting its ubiquitination and subsequent degradation. This process is crucial for maintaining appropriate levels of DRD2, which is important for cellular signaling pathways, including those involved in the response to dopamine agonists (Liu2020The).

KBTBD6 also plays a role in telomere length regulation. It has been identified as a novel gene involved in this process, with studies showing that overexpression of KBTBD6 leads to increased telomere length. This suggests that KBTBD6 may influence telomere maintenance, potentially through mechanisms involving its expression levels and interaction with other proteins in the ubiquitination pathway (Keener2023Validation). The specific molecular activities of KBTBD6 in healthy human cells, beyond its involvement in these pathways, remain to be fully elucidated.

## Clinical Significance
The KBTBD6 gene has been implicated in the regulation of pituitary adenoma sensitivity to dopamine agonist (DA) treatment, particularly in prolactinomas. Alterations in the expression of KBTBD6, along with its homolog KBTBD7, affect the degradation of the dopamine receptor D2 (DRD2), which is crucial for the effectiveness of DA treatments like cabergoline (CAB) (Liu2020The). In DA-resistant prolactinomas, KBTBD6/7 expression is higher, while DRD2 expression is lower, suggesting that KBTBD6/7 could serve as biomarkers for DA resistance (Liu2020The). Knockdown of KBTBD6/7 has been shown to increase DRD2 levels, enhancing sensitivity to CAB, whereas overexpression leads to increased resistance (Liu2020The).

The interaction between KBTBD6/7 and DRD2 involves ubiquitination-mediated degradation, which is a key factor in the regulation of DRD2 levels and, consequently, the sensitivity of pituitary tumors to DA treatment (Liu2020The). This suggests that targeting KBTBD6/7 could be a potential therapeutic strategy to overcome DA resistance in pituitary adenomas (Liu2020The). The study of KBTBD6 in this context highlights its clinical significance in the treatment of pituitary tumors.

## Interactions
KBTBD6 is involved in several protein-protein interactions, primarily functioning as a substrate adaptor for the CUL3-RING ubiquitin ligase complex. It interacts with the dopamine receptor D2 (DRD2), promoting its ubiquitination and proteasome-dependent degradation. This interaction is facilitated by the Kelch domain of KBTBD6, which is crucial for binding to DRD2. The ubiquitination of DRD2 by KBTBD6 occurs at specific lysine residues, including K221, K226, K241, K251, and K258, and is essential for regulating DRD2 protein stability (Liu2020The).

KBTBD6 also forms a heterodimeric complex with KBTBD7, sharing high structural similarity. This complex is involved in the ubiquitination of TIAM1, a process mediated by the interaction of KBTBD6/7 with GABARAP proteins through a classic ATG8-interacting motif (AIM) (Genau2015GABARAP). The interaction between KBTBD6 and GABARAP is significant for the regulation of RAC1 activity, impacting cellular processes such as autophagy and tumor progression (Genau2015GABARAP).

KBTBD6's role in these interactions highlights its importance in protein degradation pathways and its potential impact on cellular signaling and disease mechanisms.


## References


1. (Keener2023Validation) Validation of human telomere length trans-ancestry meta-analysis association signals identifiesPOP5andKBTBD6as novel human telomere length regulation genes. This article has 0 citations.

[2. (Genau2015GABARAP) Heide Marika Genau and Christian Behrends. Gabarap proteins as scaffolds in localized tiam1-rac1 signaling. Molecular &amp; Cellular Oncology, 3(1):e1027440, April 2015. URL: http://dx.doi.org/10.1080/23723556.2015.1027440, doi:10.1080/23723556.2015.1027440. This article has 2 citations.](https://doi.org/10.1080/23723556.2015.1027440)

[3. (Liu2020The) Yan Ting Liu, Fang Liu, Lei Cao, Li Xue, Wei Ting Gu, Yong Zhi Zheng, Hao Tang, Yu Wang, Hong Yao, Yong Zhang, Wan Qun Xie, Bo Han Ren, Zhuo Hui Xiao, Ying Jie Nie, Ronggui Hu, and Zhe Bao Wu. The kbtbd6/7-drd2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment. Acta Neuropathologica, 140(3):377â€“396, June 2020. URL: http://dx.doi.org/10.1007/s00401-020-02180-4, doi:10.1007/s00401-020-02180-4. This article has 20 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1007/s00401-020-02180-4)